Avadel Pharmaceuticals (AVDL) Net Income towards Common Stockholders (2016 - 2021)
Historic Net Income towards Common Stockholders for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' Net Income towards Common Stockholders fell 89424.15% to -$23.1 million in Q4 2021 from the same period last year, while for Sep 2022 it was -$23.1 million, marking a year-over-year increase of 6566.75%. This contributed to the annual value of -$85.5 million for FY2021, which is 125357.59% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Net Income towards Common Stockholders of -$23.1 million as of Q4 2021, which was down 89424.15% from -$25.7 million recorded in Q3 2021.
- In the past 5 years, Avadel Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $30.9 million in Q2 2020 and a low of -$63.9 million during Q4 2018
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$11.0 million (2020), whereas its average is -$9.2 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Net Income towards Common Stockholders soared by 52769.89% in 2017, and later crashed by 89424.15% in 2021.
- Over the past 5 years, Avadel Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$8.2 million in 2017, then crashed by 674.52% to -$63.9 million in 2018, then grew by 28.68% to -$45.5 million in 2019, then soared by 94.89% to -$2.3 million in 2020, then tumbled by 894.24% to -$23.1 million in 2021.
- Its last three reported values are -$23.1 million in Q4 2021, -$25.7 million for Q3 2021, and -$23.3 million during Q2 2021.